This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 53/6/893    most recent HYPERTENSIONAHA.108.127993v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Roser, M. Articles by Gollasch, M. Search for Related Content PubMed PubMed Citation Articles by Roser, M. Articles by Gollasch, M. Related Collections Other hypertension Other Treatment

(Hypertension. 2009;53:893.)
© 2009 American Heart Association, Inc.

Hypertension Grand Rounds

Gitelman Syndrome

Mattias Roser; Nermin Eibl; Birgit Eisenhaber; Jasmin Seringer; Mato Nagel; Sylvia Nagorka; Friedrich C. Luft; Ulrich Frei; Maik Gollasch

From the Division of Nephrology and Intensive Care Medicine (M.R., N.E., J.S., U.F., M.G.), Department of Medicine, Charité Campus Virchow, Berlin, Germany; Experimental Therapeutics Centre and Bioinformatics Institute, Agency for Science, Technology and Research (B.E.), Singapore; Experimental and Clinical Research Center and HELIOS Klinikum-Berlin (F.C.L., M.G.), Berlin, Germany; and the Center for Nephrology and Metabolic Disorders (M.N., S.N.), Weißwasser, Germany.

Correspondence to Maik Gollasch, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Nephrology/Intensive Care Medicine, Augustenburger Platz 1, D-13353 Berlin, Germany. E-mail maik.gollasch@charite.de

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Gitelman syndrome (GS) is an autosomal-recessive renal tubular disorder characterized by hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis, secondary hyperreninemic aldosteronism, and low blood pressure.^1–3 GS patients are usually diagnosed relatively late, because malaise, low blood pressure, hypokalemia, hypocalciuria, and hypomagnesemia are difficult to categorize clinically. Inactivating mutations in the SLC12A3 gene encoding the thiazide-sensitive sodium chloride cotransporter (NCCT) cause GS.² The investigators used the criteria of Bettinelli et al⁴ to identify patients with GS. More than 100 SLC12A3 mutations have been described.³ Most are missense mutations substituting conserved amino acid residues within putative functional domains of NCCT, whereas nonsense, frameshift, and splice site defects and gene rearrangements are less frequent. GS is clinically variable (men are more severely affected than women), and the combination of mutations present in each allele may determine phenotype variability.³ A heterozygous carrier state for 30 different inactivating mutations in NCCT, as well as genes responsible for Bartter syndrome, is associated with reduced blood pressure risk of hypertension in the general population.⁵ Approximately 80% of the mutation carriers had systolic blood pressure values below the mean of the entire 5124-subject cohort of the Framingham Heart Study. The mean blood pressure reduction in carriers averaged –6.3 mm Hg for the systolic and –3.4 mm Hg for the diastolic blood pressures, similar to values obtained with chronic thiazide treatment. There was a 60% reduction in the risk of developing hypertension by age 60 years. Thus, rare alleles that affect renal salt handling and blood pressure in the general population . . . [Full Text of this Article]